Showing results (391-400 of 587) with videos related to
Sort By:
Pageof 59
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)Alice Dewdney, David Cunningham, Josep Tabernero, et al.The Lancet. Oncology|April 30, 2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThomas Crosby, Christopher N Hurt, Stephen Falk, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2019
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 StudyPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.Blood Advances|June 23, 2023
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-upPier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, et al.British Journal of Cancer|September 22, 2017
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancerFrancesco Sclafani, Gina Brown, David Cunningham, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic diseaseFrancesco Sclafani, David Gonzalez de Castro, David Cunningham, et al.Annals of Hematology|November 29, 2019
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trialAndrea Kühnl, Clare Peckitt, Bijal Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III)Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, et al.Frontiers in Oncology|December 14, 2023
MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patientsHazel Lote, Florentia Mousoullou, George Vlachogiannis, et al.JAMA Oncology|February 28, 2017
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) TrialElizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, et al.Pageof 59